Ubs Group Ag Celularity Inc Transaction History

Ubs Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.17 - $0.33 $66 - $128	-389 Reduced 3.1%	12,173 $3,000
Q3 2023 Nov 09, 2023	SELL	$0.22 - $0.56 $847 - $2,156	-3,851 Reduced 23.46%	12,562 $2,000
Q2 2023 Aug 11, 2023	SELL	$0.42 - $0.81 $6,888 - $13,285	-16,402 Reduced 49.98%	16,413 $8,000
Q1 2023 May 12, 2023	BUY	$0.56 - $1.15 $10,137 - $20,818	18,103 Added 123.05%	32,815 $20,000
Q4 2022 Feb 08, 2023	BUY	$1.08 - $2.35 $8,426 - $18,334	7,802 Added 112.91%	14,712 $18,000
Q3 2022 Nov 10, 2022	SELL	$0.43 - $4.31 $1,457 - $14,610	-3,390 Reduced 32.91%	6,910 $16,000
Q2 2022 Aug 10, 2022	BUY	$2.81 - $12.91 $18,517 - $85,076	6,590 Added 177.63%	10,300 $36,000
Q1 2022 May 16, 2022	SELL	$3.81 - $9.79 $11,639 - $29,908	-3,055 Reduced 45.16%	3,710 $32,000
Q4 2021 Feb 14, 2022	BUY	$4.64 - $7.46 $17,942 - $28,847	3,867 Added 133.44%	6,765 $35,000
Q3 2021 Nov 15, 2021	BUY	$6.05 - $12.15 $17,532 - $35,210	2,898 New	2,898 $21,000

23.6M

Ticker CELU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,424,000
Market Cap $319M
Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-de...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.